Sign Up to like & get recommendations! 0
Published in 2018 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2018.0049
Abstract: Importance Aging is associated with excessive daytime sleepiness (EDS), which has been linked to cognitive decline in the elderly. However, whether EDS is associated with the pathologic processes of Alzheimer disease remains unclear. Objective To… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Neurological Sciences"
DOI: 10.1007/s10072-019-04206-6
Abstract: Although excessive daytime sleepiness (EDS) is a frequent non-motor dysfunction in Parkinson’s disease (PD), the exact pathophysiology remains elusive. This study investigates the relationship between daytime sleepiness and presynaptic monoamine transporter densities of the basal… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Psychiatric Quarterly"
DOI: 10.1007/s11126-021-09922-x
Abstract: Given the limited data currently available in the literature, the aim of this study was to investigate the risk of excessive daytime sleepiness (EDS) associated with major depression in a large sample of adolescents. The… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Sleep and Breathing"
DOI: 10.1007/s11325-019-01921-4
Abstract: Excessive daytime sleepiness (EDS) and fatigue are some of the most frequent symptoms in neurological diseases and could impact on quality of life by increasing the risk of accidents and generally affecting daily life activities.… read more here.
Sign Up to like & get recommendations! 1
Published in 2020 at "Chest"
DOI: 10.1016/j.chest.2020.02.036
Abstract: Obstructive sleep apnea (OSA) is a highly prevalent sleep disorder and subjective excessive daytime sleepiness (EDS) is the cardinal symptom for which many individuals seek medical advice. Positive airway pressure (PAP) devices, first line treatment… read more here.
Sign Up to like & get recommendations! 1
Published in 2018 at "Journal of affective disorders"
DOI: 10.1016/j.jad.2018.01.016
Abstract: BACKGROUND This study aimed to examine the one-year incidence and persistence of excessive daytime sleepiness (EDS) in rural Chinese adolescents and their risk factors. In addition, we also aimed to explore the potential bidirectional associations… read more here.
Sign Up to like & get recommendations! 1
Published in 2017 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2016.11.012
Abstract: BACKGROUND The effects of sleep disturbances on cognitive performance under distraction in multiple sclerosis (MS) are not known. The objective of the present study was to explore the association between an index of sleep (i.e.… read more here.
Sign Up to like & get recommendations! 1
Published in 2020 at "Sleep medicine reviews"
DOI: 10.1016/j.smrv.2020.101275
Abstract: Excessive daytime sleepiness (EDS) is common in patients with obstructive sleep apnea (OSA) and continues to persist in many patients despite adequate OSA treatment. EDS in OSA is associated with decreased quality of life (QOL)… read more here.
Sign Up to like & get recommendations! 0
Published in 2022 at "Arquivos de Neuro-Psiquiatria"
DOI: 10.1055/s-0042-1758399
Abstract: Abstract Background Some studies show an association between the apolipoprotein E ε4 allele (ApoEε4) and obstructive sleep apnea syndrome (OSAS), and other studies, an association between ApoEε4 and excessive daytime sleepiness (EDS), but there are… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "Renal Failure"
DOI: 10.1080/0886022x.2023.2190815
Abstract: Abstract Excessive daytime sleepiness (EDS) is associated with quality of life and all-cause mortality in the end-stage renal disease population. This study aims to identify biomarkers and reveal the underlying mechanisms of EDS in peritoneal… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2023.2204187
Abstract: ABSTRACT Introduction Lower-sodium oxybate (LXB) is a novel formulation that is approved by the US Food and Drug Administration (FDA) to treat cataplexy and excessive daytime sleepiness (EDS) in adult patients and children ≥7 years with… read more here.